49 related articles for article (PubMed ID: 34045664)
1. High tumour mutational burden and EGFR/MAPK pathway activation are therapeutic targets in metastatic porocarcinoma.
Westphal D; Garzarolli M; Sergon M; Horak P; Hutter B; Becker JC; Wiegel M; Maczey E; Blum S; Grosche-Schlee S; Rütten A; Ugurel S; Stenzinger A; Glimm H; Aust D; Baretton G; Beissert S; Fröhling S; Redler S; Surowy H; Meier F
Br J Dermatol; 2021 Dec; 185(6):1186-1199. PubMed ID: 34185311
[TBL] [Abstract][Full Text] [Related]
2. Cell-Free DNA Analysis by Whole-Exome Sequencing for Hepatocellular Carcinoma: A Pilot Study in Thailand.
Kunadirek P; Chuaypen N; Jenjaroenpun P; Wongsurawat T; Pinjaroen N; Sirichindakul P; Nookaew I; Tangkijvanich P
Cancers (Basel); 2021 May; 13(9):. PubMed ID: 34066484
[TBL] [Abstract][Full Text] [Related]
3. Genomic and transcriptional alterations in first-line chemotherapy exert a potentially unfavorable influence on subsequent immunotherapy in NSCLC.
He Y; Chen L; Zhao L; Dang S; Liu G; Sasada S; Ma PC; van Zandwijk N; Rosell R; Popper HH; Wang H; Jiang M; Guo H; Liu X; Chen S; Zhang X; Xu M; Zhu B; Liu M; Zhou C
Theranostics; 2021; 11(14):7092-7109. PubMed ID: 34093873
[No Abstract] [Full Text] [Related]
4. A novel CD74-ROS1 gene fusion in a patient with inflammatory breast cancer: a case report.
Hu H; Ding N; Zhou H; Wang S; Tang L; Xiao Z
J Med Case Rep; 2021 May; 15(1):277. PubMed ID: 34051833
[TBL] [Abstract][Full Text] [Related]
5. Influence of low tumor content on tumor mutational burden estimation by whole-exome sequencing and targeted panel sequencing.
Zhang W; Wang R; Fang H; Ma X; Li D; Liu T; Chen Z; Wang K; Hao S; Yu Z; Chang Z; Na C; Wang Y; Bai J; Zhang Y; Chen F; Li M; Chen C; Wei L; Li J; Chang X; Qu S; Yang L; Huang J
Clin Transl Med; 2021 May; 11(5):e415. PubMed ID: 34047470
[TBL] [Abstract][Full Text] [Related]
6. Recurrent Somatic
Bu R; Siraj AK; Masoodi T; Parvathareddy SK; Iqbal K; Al-Rasheed M; Haqawi W; Diaz M; Victoria IG; Aldughaither SM; Al-Sobhi SS; Al-Dayel F; Al-Kuraya KS
Front Oncol; 2021; 11():670423. PubMed ID: 34046359
[No Abstract] [Full Text] [Related]
7. Radiotherapy is associated with a deletion signature that contributes to poor outcomes in patients with cancer.
Kocakavuk E; Anderson KJ; Varn FS; Johnson KC; Amin SB; Sulman EP; Lolkema MP; Barthel FP; Verhaak RGW
Nat Genet; 2021 Jul; 53(7):1088-1096. PubMed ID: 34045764
[TBL] [Abstract][Full Text] [Related]
8. Eccrine Porocarcinoma: A Review of the Literature.
Tsiogka A; Koumaki D; Kyriazopoulou M; Liopyris K; Stratigos A; Gregoriou S
Diagnostics (Basel); 2023 Apr; 13(8):. PubMed ID: 37189532
[TBL] [Abstract][Full Text] [Related]
9. Diagnosis and Management of Porocarcinoma.
Miyamoto K; Yanagi T; Maeda T; Ujiie H
Cancers (Basel); 2022 Oct; 14(21):. PubMed ID: 36358649
[TBL] [Abstract][Full Text] [Related]
10. Porocarcinoma of the left arm: A report of a rare skin cancer case and literature review.
Signorelli C; Zanella-Cavallero L; Ranucci V; Pellicciotti A; Ruggeri EM
Clin Case Rep; 2022 Apr; 10(4):e05721. PubMed ID: 35441031
[TBL] [Abstract][Full Text] [Related]
11. Treatment of Malignant Adnexal Tumors of the Skin: A 12-Year Perspective.
Kleibert M; Płachta I; Czarnecka AM; Spałek MJ; Szumera-Ciećkiewicz A; Rutkowski P
Cancers (Basel); 2022 Feb; 14(4):. PubMed ID: 35205753
[TBL] [Abstract][Full Text] [Related]
12. Recent Advances on Immunohistochemistry and Molecular Biology for the Diagnosis of Adnexal Sweat Gland Tumors.
Macagno N; Sohier P; Kervarrec T; Pissaloux D; Jullie ML; Cribier B; Battistella M
Cancers (Basel); 2022 Jan; 14(3):. PubMed ID: 35158743
[TBL] [Abstract][Full Text] [Related]
13. Whole-exome sequencing in eccrine porocarcinoma indicates promising therapeutic strategies.
Denisova E; Westphal D; Surowy HM; Meier F; Hutter B; Reifenberger J; Rütten A; Schulz A; Sergon M; Ziemer M; Brors B; Betz RC; Redler S
Cancer Gene Ther; 2022 Jun; 29(6):697-708. PubMed ID: 34045664
[TBL] [Abstract][Full Text] [Related]
14. Whole genome and whole transcriptome genomic profiling of a metastatic eccrine porocarcinoma.
Thibodeau ML; Bonakdar M; Zhao E; Mungall KL; Reisle C; Zhang W; Bye MH; Thiessen N; Bleile D; Mungall AJ; Ma YP; Jones MR; Renouf DJ; Lim HJ; Yip S; Ng T; Ho C; Laskin J; Marra MA; Schrader KA; Jones SJM
NPJ Precis Oncol; 2018; 2(1):8. PubMed ID: 29872726
[TBL] [Abstract][Full Text] [Related]
15. Eccrine porocarcinoma arising within an area of Bowen disease.
Lowney AC; Mc Aleer MA; O'Connor K; Fitzgibbon JF; Bourke JF
Clin Exp Dermatol; 2012 Mar; 37(2):136-8. PubMed ID: 21973218
[TBL] [Abstract][Full Text] [Related]
16. Porocarcinomas harbor recurrent HRAS-activating mutations and tumor suppressor inactivating mutations.
Harms PW; Hovelson DH; Cani AK; Omata K; Haller MJ; Wang ML; Arps D; Patel RM; Fullen DR; Wang M; Siddiqui J; Andea A; Tomlins SA
Hum Pathol; 2016 May; 51():25-31. PubMed ID: 27067779
[TBL] [Abstract][Full Text] [Related]
17. Metastatic eccrine porocarcinoma.
Rehal B; Merin MR; Barr K
Cutis; 2013 Aug; 92(2):67-70. PubMed ID: 24087778
[TBL] [Abstract][Full Text] [Related]
18. [A case report of eccrine porocarcinoma].
Fumo G; Piras V; Pilloni L; Ferreli C; Pau M
Clin Ter; 2015; 166(4):e273-5. PubMed ID: 26378762
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
